<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113188</article-id><article-id pub-id-type="publisher-id">ACM-41283</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_59478875.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群失调与IgA肾病的联系
  Relationship between Intestinal Flora Imbalance and IgA Nephropathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>琪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梅</surname><given-names>峰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青海大学附属医院，青海 西宁</addr-line></aff><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1317</fpage><lpage>1322</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    IgA肾病(IgAN)是我国发病率最高的原发性肾小球肾炎，其确切的病因及发病机制迄今尚不明确，随着研究的深入，很多证据表明肠道菌群微生态失调与IgAN发生和发展相关。本文就IgAN的发病机制，肠道菌群的结构、组成，肠道菌群失调在IgAN发生、发展中的作用，通过调节肠道菌群失调对IgAN在治疗效果方面的研究进展综述如下。&lt;br/&gt;IgA nephropathy (IgAN) is the primary glomerulonephritis with the highest incidence in China. Its exact etiology and pathogenesis are still unclear, but more and more evidence shows that the imbalance of intestinal flora is closely related to the occurrence and development of IgAN. This article reviews the pathogenesis of IgA nephropathy, the structure and composition of intestinal flora, the role of intestinal flora imbalance in the occurrence and development of IgA nephropathy, and the therapeutic effect of intestinal flora imbalance on IgA nephropathy.
    
  
 
</p></abstract><kwd-group><kwd>IgA肾病，肠道菌群失调，多聚体IgA, IgA Nephropathy</kwd><kwd> Intestinal Flora Imbalance</kwd><kwd> Polymer IgA</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>IgA肾病(IgAN)是我国发病率最高的原发性肾小球肾炎，其确切的病因及发病机制迄今尚不明确，随着研究的深入，很多证据表明肠道菌群微生态失调与IgAN发生和发展相关。本文就IgAN的发病机制，肠道菌群的结构、组成，肠道菌群失调在IgAN发生、发展中的作用，通过调节肠道菌群失调对IgAN在治疗效果方面的研究进展综述如下。</p></sec><sec id="s2"><title>关键词</title><p>IgA肾病，肠道菌群失调，多聚体IgA</p></sec><sec id="s3"><title>Relationship between Intestinal Flora Imbalance and IgA Nephropathy</title><p>Qi Gao<sup>1*</sup>, Feng Mei<sup>2#</sup></p><p><sup>1</sup>Graduate School of Qinghai University, Xining Qinghai</p><p><sup>2</sup>The Affiliated Hospital of Qinghai University, Xining Qinghai</p><p><img src="//html.hanspub.org/file/71-1572051x5_hanspub.png" /></p><p>Received: Feb. 23<sup>rd</sup>, 2021; accepted: Mar. 11<sup>th</sup>, 2021; published: Mar. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/71-1572051x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>IgA nephropathy (IgAN) is the primary glomerulonephritis with the highest incidence in China. Its exact etiology and pathogenesis are still unclear, but more and more evidence shows that the imbalance of intestinal flora is closely related to the occurrence and development of IgAN. This article reviews the pathogenesis of IgA nephropathy, the structure and composition of intestinal flora, the role of intestinal flora imbalance in the occurrence and development of IgA nephropathy, and the therapeutic effect of intestinal flora imbalance on IgA nephropathy.</p><p>Keywords:IgA Nephropathy, Intestinal Flora Imbalance, Polymer IgA</p><disp-formula id="hanspub.41283-formula44"><graphic xlink:href="//html.hanspub.org/file/71-1572051x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/71-1572051x8_hanspub.png" /> <img src="//html.hanspub.org/file/71-1572051x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>IgA肾病(IgA nephropathy, IgAN)是目前世界范围内最常见的原发性肾小球疾病，也是我国最常见的肾小球疾病，我国的发病率约24% [<xref ref-type="bibr" rid="hanspub.41283-ref1">1</xref>]，是导致CKD和肾功能衰竭的主要原因，约30%~50%的IgAN患者在明确诊断后20年内进展至终末期肾病(ESRD) [<xref ref-type="bibr" rid="hanspub.41283-ref2">2</xref>]。IgAN是以IgA或IgA为主的免疫复合物在肾小球系膜区沉积的原发性肾小球疾病，是肾小球源性血尿最常见的病因 [<xref ref-type="bibr" rid="hanspub.41283-ref3">3</xref>]。其临床表现为反复发作性肉眼血尿或镜下血尿，可伴有不同程度蛋白尿，部分患者可以出现严重高血压或者肾功能不全。肠道菌群作为机体的重要组成部分之一，其组成和代谢活性发生改变可导致肠道菌群失调，对人体产生影响。</p></sec><sec id="s6"><title>2. IgAN的发病机制</title><p>IgAN是一种与多因素有关的疾病，其发病机制与遗传、环境等多种因素有关 [<xref ref-type="bibr" rid="hanspub.41283-ref4">4</xref>]。目前研究表明，与IgAN发病过程有关的主要因素，包括免疫复合物沉积 [<xref ref-type="bibr" rid="hanspub.41283-ref5">5</xref>]、粘膜免疫缺陷 [<xref ref-type="bibr" rid="hanspub.41283-ref6">6</xref>]、IgA分子异常 [<xref ref-type="bibr" rid="hanspub.41283-ref7">7</xref>]、遗传性或家族性病因 [<xref ref-type="bibr" rid="hanspub.41283-ref8">8</xref>]、微生物 [<xref ref-type="bibr" rid="hanspub.41283-ref9">9</xref>] 以及头颈免疫 [<xref ref-type="bibr" rid="hanspub.41283-ref10">10</xref>] 等方面。</p><p>由于免疫球蛋白A (IgA)广泛存在于黏膜组织，如消化道、呼吸道以及泌尿生殖系统，不少IgA肾病患者在呼吸道及消化道感染后发病，故强调黏膜免疫介导IgA肾病发病的重大意义。IgAN患者肾小球系膜区沉积免疫复合物，其主要来源于黏膜免疫系统。黏膜免疫系统由诱导部位及效应部位构成。其中，诱导部位由人体各器官淋巴组织组成，并产生B细胞，主要包括肠道相关淋巴组织(gut-associated lym phoid tissue, GALT)、支气管相关淋巴组织(bronchial-associated lymphoid tissue, BALT)、黏膜相关淋巴组织(mucosa-associated lymphoid tissue, MALT)等。与IgAN发病有关的黏膜免疫系统则主要有肠道相关淋巴组织(gut-associated lym phoid tissue, GALT)及黏膜相关淋巴组织(bronchial-associated lymphoid tissue, BALT)。近年来，研究报道提出IgAN的发病率及严重程度与肠道黏膜变化有关，Coppo等学者提出“肠–肾关联”学说 [<xref ref-type="bibr" rid="hanspub.41283-ref11">11</xref>]，当肠道黏膜免疫功能异常使肠道黏膜屏障受损时，肠道菌群产生的抗原及部分食物抗原能够导致肠道免疫耐受机制异常，使肠道对相关抗原吸收增加，进而出现肠道毒素水平升高，并通过肠道黏膜吸收进入血液，此时肠道黏膜相关淋巴组织对这些抗原产生肠道炎症反应，产生异常糖基化多聚体IgA1，形成抗原–抗体免疫复合物。在体液中游离的抗原–抗体复合物，即循环免疫复合物(CIC)，可在肾脏中肾小球系膜区沉积诱导形成IgAN。这提示肠道黏膜免疫与IgAN发病有紧密联系。</p><p>多数学者认为IgAN发病与免疫复合物的产生和沉积有关，而引起IgAN免疫复合物产生的抗原是一种低半乳糖化的Gal，即Gal缺陷IgA1分子(galactose-defi-cient IgA1, Gd-IgA1)，Gd-IgA1存在于IgAN患者的血液循环内及沉积于肾小球系膜区 [<xref ref-type="bibr" rid="hanspub.41283-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref13">13</xref>]，引起免疫炎症反应、组织损伤诱导蛋白尿产生。肠道相关淋巴组织(GALT)中免疫B细胞对肠道中异常抗原产生炎症反应后，形成二聚体IgA1 (dIgA1)或二聚体IgA2 (dIgA2)，二聚体再通过一系列聚合反应生成多聚体IgA (pIgA)。其中IgA1分子存在高度糖基化的铰链区及O-连接寡糖链以连接氨基酸，O-糖基化的关键酶是β1,3Gal转移酶(β1,3-galactosyltransferase, C1GalT1)、α2,6-唾液酸转移酶(α-2,6-sialyltransferase B, ST6GalNAc)，其作用是催化Gal及唾液酸连接N-乙酰氨Gal (N-acetylgalactosamine, GalNAc)。其中C1GalT1活性依赖于其分子伴侣cosmc [<xref ref-type="bibr" rid="hanspub.41283-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref16">16</xref>]，当O-糖基化结构缺少Gal时，即可形成Gd-IgA1，从而导致IgA1糖基化异常。研究表明，在IgAN患者中C1GalT1和cosmc水平降低，ST6GalNAc水平增高，进一步说明其相关活性影响IgA1糖基化 [<xref ref-type="bibr" rid="hanspub.41283-ref17">17</xref>]。</p></sec><sec id="s7"><title>3. 肠道菌群的结构、组成，肠道菌群失调在IgAN发生、发展中的作用</title><p>研究指出，人体胃肠道中约有400余种细菌定居，数量可达100万亿，构成胃肠道微生态。而人体肠道菌群大致分为三个大类：包括有益菌(益生菌)，主要包括各种双歧杆菌、乳酸杆菌等，可以合成各种维生素，参与食物消化，促进肠道蠕动，抑制致病菌群生长，分解有害、有毒物质等；还包括有害菌(如：大肠杆菌)，可引发多种疾病(如：肠道感染性疾病、肠道肿瘤)，产生有毒、有害物质(如：氨化物，可进一步诱发肠道肿瘤等疾病)，这些都影响正常的生理功能；又包括中性菌，即具有条件致病细菌，如大肠杆菌、肠球菌、变形杆菌等，在正常情况下对健康有益，当出现增殖失控或从肠道移位时，可引发相关疾病。人体和肠道菌群之间处于相对恒定及互益的共生稳态，这对于人体免疫系统耐受和抵御病原体侵袭有重大影响 [<xref ref-type="bibr" rid="hanspub.41283-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref19">19</xref>]。正常情况下，当肠道微生态平衡时，肠道菌群可以促进肠道黏膜上皮细胞之间连接来抵御病原体入侵，同时促进肠道形成黏蛋白(MUC2等)，起到增加肠道黏膜屏障功能作用。在共生菌群联合作用下，肠道菌群促使肠道淋巴滤泡上皮细胞表达核苷酸结合寡聚化结构域蛋白1 (NOD-1)及肠黏膜表面Toll样受体(TLRs)生成，两者可诱导肠道相关淋巴组织(GALT)形成和分化，进而调节肠道的免疫应答机制 [<xref ref-type="bibr" rid="hanspub.41283-ref20">20</xref>]。研究指出，肠道菌群对T淋巴细胞的发育和分化有着重要影响，肠道菌群可以通过调节Ｔ淋巴细胞亚群的分化、增殖及细胞因子的分泌等，改变肠道免疫系统状态、影响肠道相关淋巴组织的功能 [<xref ref-type="bibr" rid="hanspub.41283-ref21">21</xref>]。肠道菌群与肠黏膜免疫系统之间也存在紧密联系，肠道通透性增加、肠黏膜损伤、肠道菌群失调是肠屏障功能障碍发生的重要表现。即使没有外源入侵，肠道菌群自身异常导致共生细菌生态失调和有害细菌的过度生长，直接影响肠道相关淋巴组织(GALT)调节，进一步激活产生T细胞依赖性IgA，刺激IgA过度生成 [<xref ref-type="bibr" rid="hanspub.41283-ref22">22</xref>]。所以，肠道菌群失调在IgAN发病机制中起重要作用。</p><p>目前已通过实验研究发现IgAN患者的肠道微生物群存在生态失调 [<xref ref-type="bibr" rid="hanspub.41283-ref20">20</xref>]。IgAN患者与健康对照组的肠道和唾液微生物群和代谢组成存在差异 [<xref ref-type="bibr" rid="hanspub.41283-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref23">23</xref>]，其中De Angelis等 [<xref ref-type="bibr" rid="hanspub.41283-ref22">22</xref>] 采用选择性培养基对主要可培养菌群进行鉴定，使用16SrRNA进行细菌标签编码的flx钛扩增子焦糖测序，联合分别测定细菌总数和代谢活性；并采用Biochrom 30系列氨基酸分析仪和气相色谱–质谱/固相微萃取(GC-MS/SPME)的代谢组学分析法，将进展型IgAN患者和非进展型IgANN患者与健康对照组的肠道微生物群和代谢组组成进行对比后，发现IgAN患者粪便中共生菌的数量较对照组明显减少，如拟杆菌、乳杆菌、双歧杆菌等，而有害菌的数量增加，如大肠杆菌、放线菌等。其机制主要与构成这些革兰氏阴性杆菌外膜的一种磷脂细菌脂多糖(lipopolysaccharide, LPS)有关。LPS信号传导的主要成分则是膜CD14、LPS结合受体和TLR4，这些成分影响慢性炎性疾病的病变过程。据研究推测，CD14启动子区域中的基因变异可能改变CD14的表达，并且可反过来影响炎性疾病包括IgAN等疾病发展。而CD14/-159多态性与IgAN进展性病例的相关性也表明LPS膜受体的遗传修饰可以调节炎症反应的水平，并且是IgAN进展的标志物 [<xref ref-type="bibr" rid="hanspub.41283-ref24">24</xref>]。肠黏膜表面的Toll样受体(TLR)识别微生物的分子模式有脂多糖(LPS) (TLR4)和脂磷壁酸(TLR2)，在肠道损伤和修复中TLR的微生物群信号传导起关键作用，有改变肠道屏障功能作用。Qin [<xref ref-type="bibr" rid="hanspub.41283-ref25">25</xref>] 等通过研究发现，LPS也与Gd-IgA有关，用细菌LPS激活培养IgAN患者和健康对照组的外周血B淋巴细胞中的TLR4，并诱导健康对照组分子伴侣Cosmc甲基化，结果导致半乳糖基转移酶的活性降低，影响IgA1半乳糖化。这些均提示肠道菌群与IgAN的发病密切相关。</p></sec><sec id="s8"><title>4. 通过调节肠道菌群失调对IgAN在治疗效果方面的研究进展</title><p>研究提出，使用益生菌、益生元、合生元可调节肠道菌群的构成、种类及比例，从而改善肠道微生态，促进益生菌生长，在慢性肾脏病、肾功能不全等肾脏疾病的治疗起到一定的干预作用 [<xref ref-type="bibr" rid="hanspub.41283-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref27">27</xref>]。基于上述肠道菌群与IgAN机制的联系，我们应该重视肠道炎症、肠道菌群变化等对IgAN治疗的影响。由此可以推测：针对调节肠道菌群失调，维持肠道菌群平衡的治疗，改善肠道微环境及肠黏膜免疫起到预防、控制及治疗IgAN。Jonathan等 [<xref ref-type="bibr" rid="hanspub.41283-ref28">28</xref>] 通过使用口服广谱抗生素混合物(包括甲硝唑、新霉素、万古霉素、阿莫西林)，每周两次，连续灌胃8周，得出抗生素调节IgA肾病小鼠肠道菌群后治疗IgA肾病小鼠，其得到控制，进而证实使用抗生素调节肠道菌群失调在IgAN发生、发展中的重要关系，以及通过口服抗生素调节肠道菌群对IgAN治疗的影响。研究指出，肠道内部分细菌可产生能特异性裂解IgA1及其免疫复合物的IgA蛋白酶，从而起到清除肾小球系膜区沉积的IgA1免疫复合物的作用有关 [<xref ref-type="bibr" rid="hanspub.41283-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref30">30</xref>]。但目前仍没有确切的研究结论提出使用益生菌、益生元、合生元等调节肠道菌群治疗方法，可对IgAN患者治疗的起到一定的作用。所以，调节肠道菌群治疗在IgAN的治疗中影响仍存在巨大的研究潜力，值得继续研究。</p><p>其次，相关研究表明控制肠道感染也在IgAN治疗中有重要意义。NEFIGAN试验将布地奈德用于肠道局部来减轻肠道炎症反应，其在回盲部释放相关活性物质抑制肠道反应，试验结果提示使用布地奈德可有效缓解IgAN患者临床症状，使IgAN患者尿蛋白和血肌酐降低、肾小球滤过率(eGFR)升高。得出该治疗方式可有效地降低IgAN患者尿蛋白和血肌酐水平，同时提高肾小球滤过率(eGFR)水平，来达到改善肾功能的目的。同时研究中未观察到与局部使用皮质类固醇激素相关的重大副作用与常规激素比较，本药物有代谢率较高、全身暴露量较低的优点。所以，得出局部使用布地奈德可能成为治疗IgAN一种新的治疗方式的结论 [<xref ref-type="bibr" rid="hanspub.41283-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.41283-ref32">32</xref>]。</p></sec><sec id="s9"><title>5. 小结及研究展望</title><p>综上所述，近年来多项研究显示了肠道微生物群在肠道黏膜免疫中的关键作用，突出了微生物群功能在疾病发展中的重要性。目前关于IgAN发病机制的研究逐渐深入，越来越多的组织免疫学、基因学证据表明，肠道黏膜免疫功能异常、肠道菌群失调参与IgAN的发生及发展。关于IgAN患者肠道菌群的相关研究已经成为对IgA肾病发病机制及相关治疗的研究的新目标之一。通过对于IgAN与肠道菌群关系的深入研究，可以提出通过调节肠道菌群的方式改善肠道黏膜免疫功能用来预防、治疗或改善IgAN预后的新观点。这些研究无疑会对将来IgAN的治疗及预防起到巨大的推动作用。</p></sec><sec id="s10"><title>文章引用</title><p>高 琪,梅 峰. 肠道菌群失调与IgA肾病的联系Relationship between Intestinal Flora Imbalance and IgA Nephropathy[J]. 临床医学进展, 2021, 11(03): 1317-1322. https://doi.org/10.12677/ACM.2021.113188</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41283-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y., Zhang, Z., Zhuo, L., Chen, D.-P. and Li, W.-G. (2018) The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chinese Medical Journal, 131, 731-735. 
&lt;br&gt;https://doi.org/10.4103/0366-6999.226906</mixed-citation></ref><ref id="hanspub.41283-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, I.S. (2014) Pathology of IgA Nephropathy. Nature Reviews Nephrology, 10, 445-454.</mixed-citation></ref><ref id="hanspub.41283-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">黎磊石, 刘志红, 张馨. IgA肾病[M]//黎磊石, 刘志红. 中国肾脏病学. 北京: 人民军医出版社, 2008: 442-464.</mixed-citation></ref><ref id="hanspub.41283-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhai, Y., Qi, Y., Long, X., Dou, Y., Liu, D., Cheng, G.Y., et al. (2019) Elevated hsa-miR-590-3p Expression Down-Regulates HMGB2 Expression and Contributes to the Severity of IgA Nephropathy. Journal of Cellular and Molecular Medicine, 23, 7299-7309. &lt;br&gt;https://doi.org/10.1111/jcmm.14582</mixed-citation></ref><ref id="hanspub.41283-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wehbi, B., Oblet, C., Boyer, F., Huard, A., Druilhe, A., Paraf, F., et al. (2019) Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation. Journal of the American Society of Nephrology, 30, 1238-1249. &lt;br&gt;https://doi.org/10.1681/ASN.2018111089</mixed-citation></ref><ref id="hanspub.41283-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Launay, P., Grossetête, B., Arcos-Fajardo, M., Gaudin, E., Torres, S.P., Beaudoin, L., et al. (2000) Fcα Receptor (CD89) Mediates the Development of Immunoglobulin A (IgA) Nephropathy (Berger’s Disease). Evidence for Pathogenic Soluble Receptor-Iga Complexes in Patients and CD89 Transgenic Mice. Journal of Experimental Medicine, 191, 1999-2009. &lt;br&gt;https://doi.org/10.1084/jem.191.11.1999</mixed-citation></ref><ref id="hanspub.41283-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C., Ye, M., Zhao, Q., Xia, M., Liu, D., He, L., et al. (2019) Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy. American Journal of Nephrology, 49, 307-316. 
&lt;br&gt;https://doi.org/10.1159/000499110</mixed-citation></ref><ref id="hanspub.41283-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zhong, Z., Feng, S., Shi, D., Xu, R., Yin, P., Wang, M., et al. (2019) Association of FCRL3 Gene Polymorphisms with IgA Nephropathy in a Chinese Han Population. DNA and Cell Biology, 38, 1155-1165. 
&lt;br&gt;https://doi.org/10.1089/dna.2019.4900</mixed-citation></ref><ref id="hanspub.41283-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, N., Fan, J., Wang, B., Wang, D., Feng, P., Yang, Q., et al. (2017) Expression Profile of BAFF in Peripheral Blood from Patients of IgA Nephropathy: Correlation with Clinical Features and Streptococcus Pyogenes Infection. Molecular Medicine Reports, 15, 1925-1935. &lt;br&gt;https://doi.org/10.3892/mmr.2017.6190</mixed-citation></ref><ref id="hanspub.41283-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Johnston, J.J. and Douglas, R. (2018) Adentonsillar Microbiome: An Update. Postgraduate Medical Journal, 94, 398-403. &lt;br&gt;https://doi.org/10.1136/postgradmedj-2018-135602</mixed-citation></ref><ref id="hanspub.41283-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Coppo, R. (2015) The Intestine-Renal Connection in IgA Nephropathy. Nephrology Dialysis Transplantation, 30, 360-366. &lt;br&gt;https://doi.org/10.1093/ndt/gfu343</mixed-citation></ref><ref id="hanspub.41283-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Magistroni, R., D’Agati, V.D., Appel, G.B. and Kiryluk, K. (2015) New Developments in the Genetics, Pathogenesis, and Therapy of IgA Nephropathy. Kidney International, 88, 974-989. 
&lt;br&gt;https://doi.org/10.1038/ki.2015.252</mixed-citation></ref><ref id="hanspub.41283-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803.  
&lt;br&gt;https://doi.org/10.1681/ASN.2011050464</mixed-citation></ref><ref id="hanspub.41283-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wyatt, R.J. and Julian, B.A. (2013) IgA Nephropathy. The New England Journal of Medicine, 368, 2402-2414.  
&lt;br&gt;https://doi.org/10.1056/NEJMra1206793</mixed-citation></ref><ref id="hanspub.41283-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Smith, A.C., Molyneux, K., Feehally, J. and Barratt, J. (2006) O-Glycosylation of Serum IgA1 Antibodies against Mucosal and Systemic Antigens in IgA Nephropathy. Journal of the American Society of Nephrology, 17, 3520-3528.  
&lt;br&gt;https://doi.org/10.1681/ASN.2006060658</mixed-citation></ref><ref id="hanspub.41283-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Novak, J., Moldoveanu, Z., Julian, B.A., Raska, M., Wyatt, R.J., Suzuki, Y., et al. (2011) Aberrant Glycosylation of IgA1 and Anti-Glycan Antibodies in IgA Nephropathy: Role of Mucosal Immune System. Advances in Oto-Rhino-Laryngology, 72, 60-63. &lt;br&gt;https://doi.org/10.1159/000324607</mixed-citation></ref><ref id="hanspub.41283-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hooper, L.V. and Gordon, J.I. (2001) Commensal Host-Bacterial Relationships in the Gut. Science, 292, 1115-1118.  
&lt;br&gt;https://doi.org/10.1126/science.1058709</mixed-citation></ref><ref id="hanspub.41283-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Anders, H.J., Andersen, K. and Stecher, B. (2013) The Intestinal Microbiota, A Leaky Gut, and Abnormal Immunity in Kidney Disease. Kidney International, 83, 1010-1016. &lt;br&gt;https://doi.org/10.1038/ki.2012.440</mixed-citation></ref><ref id="hanspub.41283-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bouskra, D., Brézillon, C., Bérard, M., Werts, C., Varona, R., Gomperts Boneca, I., et al. (2008) Lymphoid Tissue Genesis Induced by Commensals through NOD1 Regulates Intestinal Homeostasis. Nature, 456, 507-510.  
&lt;br&gt;https://doi.org/10.1038/nature07450</mixed-citation></ref><ref id="hanspub.41283-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mahmoodpoor, F., Rahbar Saadat, Y., Barzegari, A., Ardalan, M. and Vahed, S.Z. (2017) The Impact of Gut Microbiota on Kidney Function and Pathogenesis. Biomedicine &amp; Pharmacotherapy, 93, 412-419.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2017.06.066</mixed-citation></ref><ref id="hanspub.41283-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">De Angelis, M., Montemurno, E., Piccolo, M., Vannini, L., Lauriero, G., Maranzano, V., et al. (2014) Microbiota and Metabolome Associated with Immunoglobulin a Nephropathy (IgAN). PLoS ONE, 9, e99006.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0099006</mixed-citation></ref><ref id="hanspub.41283-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bunker, J.J. and Albert, B. (2018) IgA Responses to Microbiota. Immunity, 49, 211-224.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2018.08.011</mixed-citation></ref><ref id="hanspub.41283-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Piccolo, M., De Angelis, M., Lauriero, G., Montemurno, E., Di Cagno, R., Gesualdo, L., et al. (2015) Salivary Microbiota Associated with Immunoglobulin a Nephropathy. Microbial Ecology, 70, 557-565.  
&lt;br&gt;https://doi.org/10.1007/s00248-015-0592-9</mixed-citation></ref><ref id="hanspub.41283-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, H.J., Shin, J.H., Yang, S.H., Chae, D.-W., Kim, H., Lee, D.-S., et al. (2003) Association of the CD14 Gene-159C Polymorphism with Progression of IgA Nephropathy. Journal of Medical Genetics, 40, 104-108.  
&lt;br&gt;https://doi.org/10.1136/jmg.40.2.104</mixed-citation></ref><ref id="hanspub.41283-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Qin, W., Zhong, X., Fan, J.M., Zhang, Y.J., Liu, X.R. and Ma, X.Y. (2008) External Suppression Causes the Low Expression of the Cosmc Gene in IgA Nephropathy. Nephrology Dialysis Transplantation, 23, 1608-1614.  
&lt;br&gt;https://doi.org/10.1093/ndt/gfm781</mixed-citation></ref><ref id="hanspub.41283-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Nakabayashi, I., Nakamura, M., Kawakami, K., Ohta, T., Kato, I., Uchida, K., et al. (2011) Effects of Synbiotic Treatment on Serum Level of Pcresol in Haemodialysis Patients: A Preliminary Study. Nephrology Dialysis Transplantation, 26, 1094-1098. &lt;br&gt;https://doi.org/10.1093/ndt/gfq624</mixed-citation></ref><ref id="hanspub.41283-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Rossi, M., Johnson, D.W., Morrison, M., Pascoe, E.M., Coombes, J.S., Forbes, J.M., et al. (2016) Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clinical Journal of the American Society of Nephrology, 11, 223-231. &lt;br&gt;https://doi.org/10.2215/CJN.05240515</mixed-citation></ref><ref id="hanspub.41283-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Chemouny, J.M., Gleeson, P.J., Abbad, L., Lauriero, G., Boedec, E., Le Roux, K., et al. (2019) Modulation of the Microbiota by Oral Antibiotics Treats Immunoglobulin a Nephropathy in Humanized Mice. Nephrology Dialysis Transplantation, 34, 1135-1144. &lt;br&gt;https://doi.org/10.1093/ndt/gfy323</mixed-citation></ref><ref id="hanspub.41283-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Knoppova, B., Reily, C., Maillard, N., Rizk, D.V., Moldoveanu, Z., Mestecky, J., et al. (2016) The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Frontiers in Immunology, 12, 117-142.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2016.00117</mixed-citation></ref><ref id="hanspub.41283-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Li, X.Y., Shen, H.C., Mao, N., Wang, H.L., Cui, L.K., et al. (2016) Bacterial IgA Protease-Mediated Degradation of agIgA1 and agIgA1 Immune Complexes as a Potential Therapy for IgA Nephropathy. Scientific Reports, 6, Article No. 30964. &lt;br&gt;https://doi.org/10.1038/srep30964</mixed-citation></ref><ref id="hanspub.41283-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Smerud, H.K., Bárány, P., Lindstrom, K., Fernström, A., Sandell, A., Påhlsson, P., et al. (2011) New Treatment for IgA Nephropathy: Enteric Budesonide Targeted to the Ileocecal Region Ameliorates Proteinuria. Nephrology Dialysis Transplantation, 26, 3237-3242. &lt;br&gt;https://doi.org/10.1093/ndt/gfr052</mixed-citation></ref><ref id="hanspub.41283-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Filiopoulos, V. and Vlassopoulos, D. (2012) Steroids with Local Enteric Action in IgA Nephropathy and the Association between Kidney and Bowel Disease. Nephrology Dialysis Transplantation, 27, 1265-1266.  
&lt;br&gt;https://doi.org/10.1093/ndt/gfr743</mixed-citation></ref></ref-list></back></article>